6533b85efe1ef96bd12c0959

RESEARCH PRODUCT

CD1a expression by Barrett's metaplasia of gastric type may help to predict its evolution towards cancer

Giovanni ZummoRita AnzaloneFrancesca RappaG. La RoccaFrancesco Cappello

subject

Cancer Researchmedicine.medical_specialtyDiseaseBiologyCD1aGastroenterologyAntigens CD1Barrett EsophagusStomach NeoplasmsMetaplasiaInternal medicinemedicineCarcinomaGastric mucosaHumansMolecular DiagnosticsRetrospective StudiesMetaplasiaintegumentary systemStomachCancerDendritic CellsBarrett’s metaplasiamedicine.diseaseImmunohistochemistrymedicine.anatomical_structureCell Transformation NeoplasticOncologyDysplasiaGastric MucosaCancer researchBiomarker (medicine)Barrett’s metaplasia; CD1a; carcinogenesismedicine.symptomBarrett's metaplasiacarcinogenesis

description

As emerging in the recent literature, CD1a has been regarded as a molecule whose expression may reflect tumour evolution. The aim of the present work was to investigate the expression of CD1a in a series of Barrett's metaplasia (BM), gastric type (GTBM), with and without follow-up, in order to analyse whether its expression may help to diagnose this disease and to address the outcome. Indeed, GTBM may be confused sometimes with islets of ectopic gastric mucosa and its evolution towards dysplasia (Dy) or carcinoma (Ca) could not be foreseen. We showed a significant higher expression of CD1a in GTBM than in both Dy and Ca; nevertheless, the number of positive GTBM was significantly lower in the group of cases that at follow-up underwent Dy or Ca. Our data address that CD1a may be a novel biomarker for BM and that its expression may help to predict the prognosis of this pathology.

yearjournalcountryeditionlanguage
2005-03-01
http://hdl.handle.net/10447/30885